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Abstract  
 
Inhibitors of the proteasome have found broad therapeutic applications 
however, they show severe toxicity due to the abundance of proteasomes in 
healthy cells. In contrast, inhibitors of the immunoproteasome, which is 
upregulated during disease states, are less toxic and have increased 
therapeutic potential including against autoimmune disorders. In this project, 
we report argyrin B, a natural product cyclic peptide to be a reversible, non-
competitive inhibitor of the immunoproteasome. Argyrin B showed selective 
inhibition of the β5i and β1i sites of the immunoproteasome over the β5c and 
β1c sites of the constitutive proteasome with nearly 20-fold selective inhibition 
of β1i over the homologous β1c. Molecular modelling attributes the β1i over 
β1c selectivity to the small hydrophobic S1 pocket of β1i and β5i over β5c to 
site-specific amino acid variations that enable additional bonding interactions 
and stabilization of the binding conformation. These findings facilitate the 
design of immunoproteasome selective and reversible inhibitors that may 
have a greater therapeutic potential and lower toxicity. 
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Introduction 
Protein degradation is involved in the regulation of key pathways such as cell 
cycle control, DNA repair and apoptosis, where the ubiquitin-proteasome 
system is the main pathway for the degradation of cytosolic proteins deemed 
redundant, misfolded or toxic(Ciechanover, 2005; Suh et al., 2013). The 20S 
core of the proteasome contains the three proteolytic sites through which 
proteins are cleaved into oligopeptides by the chymotrypsin- (β5) trypsin- (β2) 
and caspase- (β1) like activities(Heinemeyer, Ramos, & Dohmen, 2004; 
Orlowski & Wilk, 2000). Inhibitors of the proteasome act in one or more of the 
active sites and have shown broad therapeutic applications, particularly for 
multiple myeloma and mantle cell lymphoma. However, since the proteasome 
is required for normal cell function its inhibition becomes associated with 
severe toxicity (Crawford, Walker, & Irvine, 2011; Genin, Reboud-Ravaux, & 
Vidal, 2010; Goldberg, 2012; Alexei F. Kisselev, van der Linden, & Overkleeft, 
2012; Kuhn et al., 2007; Moore, Eustáquio, & McGlinchey, 2008; Parlati et al., 
2009; Pellom & Shanker, 2012; Shah, Biran, & Vesole, 2016; Shivakumar & 
Jagganath, 2006; Sun et al., 2015; Teicher & Tomaszewski, 2015; Wu et al., 
2010; Zhang et al., 2016, 2014). Cells in disease states, where the demand 
for protein degradation is higher, are capable of producing 
immunoproteasomes in which the catalytic β1c, β2c and β5c subunits of the 
constitutive proteasome are replaced by the homologous β1i, β2i and β5i 
while all other subunits remain unchanged(Kniepert & Groettrup, 2014; 
Yewdell, 2005). As a result of these structural changes the cleavage 
specificities of the immunoproteasome and constitutive proteasome differ and 
immunoproteasome preferentially cleaves after hydrophobic amino 
acids(Gaczynska, Rock, Spies, & Goldberg, 1994). Besides the constitutive 
proteasome and immunoproteasome two additional intermediate subtypes 
exist, which contain a mixture of constitutive and immunoproteasome subunits 
i.e either immunosubunit β5i, and constitutive subunits β1ic and β2c, or 
immunosubunits β1i and β5i, and constitutive subunit β2c.  Intermediate 
proteasomes are abundant in normal tissues (between one-third and one-half 
of total proteasome content) and are also present in human tumor cells (10-
20%) and dendritic cells (30-50%) and exhibit trypsin and chymotrypsin-like 
activities that are in-between those of the constitutive and the 
immunoproteasome. As such, intermediate proteasomes produce a unique 
set of antigenic peptides and together with the immunoproteasome they 
represent valuable targets for cancer immunotherapy (Dahlmann, Ruppert, 
Kuehn, Merforth, & Kloetzel, 2000; Guillaume et al., 2010, 2012; Vigneron & 
Van den Eynde, 2014). 
Most existing proteasome inhibitors block the active sites of both the 
constitutive proteasome and immunoproteasome at similar potencies(Bakas 
et al., 2018; Kuhn & Orlowski, 2012; Parlati et al., 2009). However, significant 
advancements in crystal structure elucidations have enabled the identification 
of sufficient structural differences in the binding pockets of the different forms 
of proteasomes (Groll, Berkers, Ploegh, & Ovaa, 2006; Harshbarger, Miller, 
Diedrich, & Sacchettini, 2015; Huber et al., 2012)(Santos et al., n.d.) to allow 
for selective structure-based drug design and selective inhibition.  These 
structural differences have allowed the design of peptide epoxyketone 
derivatives (Ho, Bargagna-Mohan, Wehenkel, Mohan, & Kim, 2007) (Carmony 
et al., 2012), and peptidyl boronate ML604440(Basler et al., 2012) that bind 
specifically at the β1i site. Furthermore, oxathiazolones have been reported to 
inhibit β5i with a remarkable 4700-fold selectivity over the constitutive 
proteasome(Fan, Angelo, Warren, Nathan, & Lin, 2014). Peptide epoxy-
ketones represent another class of β5i selective inhibitors (de Bruin et al., 
2014; Dubiella et al., 2014; Fan et al., 2014; Groll, Korotkov, Huber, de 
Meijere, & Ludwig, 2015; Koroleva et al., 2015) among which PR-957, an 
analogue of carfilzomib, shows 20 to 40-fold selectivity towards β5i in MOLT-4 
cells where both forms of the proteasome are expressed and showed 
evidence of disease reversal  of rheumatoid arthritis mouse 
models(Muchamuel et al., 2009). PR-924, a selective inhibitor of the 
immunoproteasome with up to 250-fold selectivity towards β5i over β5c(Huber, 
Heinemeyer, de Bruin, Overkleeft, & Groll, 2016) selectively inhibited growth 
and triggered apoptosis in multiple myeloma cells over normal cells, validating 
the β5i site as a target for multiple myeloma treatment(Singh et al., 2011). 
These inhibitors are irreversible and covalently modify the active site 
threonine forming a protein-drug adduct. Landsteiner and Jacobs over 80 
years ago(Landsteiner & Jacobs, 1935) discovered a direct association 
between a chemical’s propensity to bind covalently to protein and immune 
sensitization with the risk of developing idiosyncratic adverse drug reactions 
(IADR)(Zhou, Chan, Duan, Huang, & Chen, 2005). From this perspective, 
reversible inhibitors can offer an advantage as they can potentially inhibit at 
low nanomolar concentrations without producing protein adducts that trigger 
drug hypersensitivity. Recently, reversible β5i selective inhibitors have been 
reported to selectively induce cell death in malignant myeloma cells (Santos 
et al., n.d.) and to promote long-term acceptance of cardiac allografts in mice 
by regulating immune activity(Sula Karreci et al., 2016). 
Argyrins are a family of cyclic peptides derived from the myxobacterium 
Archangium gephyra analogues of which have shown to be potent, reversible 
inhibitors of the constitutive proteasome with mechanisms distinct to existing 
therapeutics(Bülow et al., 2010; Ferrari et al., 1996; Loizidou & Zeinalipour-
Yazdi, 2014; Selva et al., 1996; Stauch et al., 2010). Argyrin B (Figure 1), 
initially discovered in screening for antibiotics, has displayed some 
antibacterial as well as antifungal activities(Nyfeler et al., 2012). In human B 
cells, argyrin B exhibited immunoglobulin G inhibition and showed reduced 
activity of T and B lymphocytes in murine studies, highlighting its strong 
immunosuppressive effects(Sasse et al., 2002). Taking into consideration 
both the proteasome inhibition as well as immunosuppressive effects of 
argyrin B, in this project we wished to further investigate the potential for 
selective inhibition of the immunoproteasome. Active site inhibition of the β5c, 
β1c subunits of the constitutive proteasome and the β5i, β1i subunits of the 
immunoproteasome were investigated using purified enzyme assays 
alongside molecular modelling. Kinetic assays revealed that argyrin B 
selectively inhibits β1i over β1c with 20-fold selectivity and shows low 
micromolar Ki values for both β1i and β5i.. Molecular modeling simulations 
reveal that the increased hydrophobicity and smaller size of the β1i S1 pocket 
contributes to the selective binding of argyrin B while the site specific amino 
acid variation A27S (from β5c to β5i) enables additional hydrogen bonding at 
the β5i site that may further stabilize binding compared to β5c. 
Materials and methods 
Material 
20S proteasome (purified human erythrocyte), 20S immunoproteasome 
(purified human enzyme), NBS 96-well microplates, 7-amino-4-
methylcoumarin (AMC) standards, Z-Leu-Leu-Glu-AMC, Suc-Leu-Leu-Val-
Tyr-AMC, epoxomycin, sodium dodecyl sulfate (SDS) and vinyl sulfone (Ada-
(Ahx3)-(Leu)3-vinyl sulfone) were purchased from Enzo Life Sciences, Exeter 
UK. Ac-Pro-Ala-Leu-AMC was purchased from BioTechne Abingdon, UK, 
dimethyl sulfoxide (DMSO) from Fisher Scientific, Loughborough, UK and 
Argyrin B was a donation from Novartis. 
Purified enzyme assays 
Substrate and inhibitor reagents were dissolved in DMSO for stock solutions 
and subsequently diluted in proteasome assay buffer to desired 
concentrations.  Assay reagents were added to 96-well plates to a final 
volume of 50 µl per well, throughout. Concentrations of the 20S proteasome 
and 20S immunoproteasome were maintained constant at 0.1 µg/well. AMC 
standards were prepared from a 1:2 serial dilution of 8 µM to 0.25 µM and 
blank. All purified enzyme reactions were performed at 37 ᵒC and the 
liberation of AMC was measured over time using a BMG Labtech 
fluorescence plate reader set at 355/460 nm (excitation/emission). Positive 
controls were performed by the reaction of proteasome or immunoproteasome 
with active site specific substrates: Z-LLE-AMC (β1), Ac-PAL-AMC (β1i) and 
Suc-LLVY-AMC (β5/ β5i). Negative controls were performed using 
epoxomycin a potent inhibitor of β5/ β5i and vinyl sulfone a potent inhibitor of 
β1/ β1i. Blanks were performed with substrate only and additional controls for 
solvent (DMSO) concentration were used where applicable.  
Using 0.1 µg/well of enzyme, a range of at least 7 substrate concentrations 
were used to generate Michaelis-Menten plots for Michaelis-Menten constant 
(Km) analysis at each active site. Subsequent Km values were used as the 
single substrate concentration in IC50 plots that covered a logarithmic range of 
at least 10 argyrin B concentrations. For kinetic assays to determine inhibition 
constant (Ki), the following inhibitor and substrate concentrations were used: 
argyrin B concentrations ranged from estimated IC50 value (β1c = 183.7 µM, 
β1i = 10.4 µM, β5 = 11.4 µM, β5i = 10.3 µM) x 0, 0.33, 1 and 3, whilst 
substrate concentration covered Km (β1 = 95.4 µM, β1i = 69.9 µM, β5 = 72.4 
µM, β5i = 89.8 µM) x 2.5, 1.25, 0.625, 0.3125 and 0.15625.   
Assays were performed with triplicates at every control and concentration 
variant. For each replicate, the initial rate of reaction was determined from the 
linear phase of the graph at which less than 10% of substrate had been 
consumed. GraphPad Prism 6 non-linear curve fitting analysis was used for 
calculation of Km, IC50 and Ki values. For Km a Michaelis-Menten plot as the 
preferred model, whilst for IC50 analysis, a normalised response curve was fit 
against logarithmic inhibitor concentration allowing for variable slope function. 
Data are reported with mean, SEM and 95% confidence interval. A standard, 
unpaired, t-test was used to analyse significance between the 3 IC50 value 
repeats of argyrin B at different active sites at 95% confidence level. 
Alongside Km and Vmax values, Akaike’s information criterion (AICc)(Motulsky 
& Christopoulos, n.d.) and the F test hypothesis testing approach at p<0.05 
were used to determine  the best-fit simultaneous non-linear regression 
analysis model between competitive, non-competitive, uncompetitive and 
mixed inhibition that subsequently calculated Ki. . Estimates of the inhibition 
constant Ki are reported with SEM and 95% confidence intervals.  
Computational methods 
All 3-dimensional structures were obtained from RCSB Protein Data Bank and 
prepared using the molecular graphics package PyMOL (v1.7.4.5). An argyrin 
B structure was isolated from PDB:4FN5(Nyfeler et al., 2012) and its 
geometry optimised using the Molecular Mechanics with UFF force field 
function of Avogadro(Hanwell et al., 2012). The Human constitutive 20S 
proteasome structural data was available from PDB:4R3O(Harshbarger et al., 
2015). β1, β2 and β5 active sites were cut for residues within 28 Å from the 
catalytic Thr1 position of each active subunit chain from the same β-ring on 
the same monomer using PyMOL. IP structural data was obtained from 
PDB:3UNH(Huber et al., 2012) murine IP and subsequently modified in order 
to create a humanised IP model as follows: human active site sequences for 
β1i, β2i and β5i (UniProt: P28065, P40306, P28062, respectively) were 
aligned to murine immunoproteasome FASTA sequences using EMBL-EBI 
ClustalOmega, EMBOSS Smith-Waterman alignment algorithm followed by 
identification of the conserved amino acids. Subsequently, the amino acid 
mutation utility of SwissPDB viewer (v.4.10) was used to mutate variable, 
individual amino acids of murine IP to those of the corresponding human IP. 
Active sites were subsequently cut as described for the constitutive 
proteasome.  
AutoDock (v.4.2.6) was used to simulate argyrin B binding(Morris et al., 2009) 
at the active sites of the immunoproteasome and constitutive proteasome. 
The grid box was set at 70x, 70y, 70z dimensions, centred based on Thr1 co-
ordinates on the active subunit chains as follows: 23.238, -78.082, -11.152 for 
β1i, 52.961, -24.734, -1.942 for β5i and -44.697, 77.350, -80.590 for β1c, -
42.794, 25.372, -104.397 for β5c.  
Argyrin B was allowed rotational freedom at the bonds connecting the 
tryptophan rings to the peptide cycle, as well as the Trp2-OMethoxy bond 
while the constitutive proteasome and immunoproteasome active sites were 
treated as non-flexible.  A genetic algorithm with 50 runs was selected for all 
docking experiments. Each docking experiment was repeated 10 times and 
for each set of 10 replicate best binding energies, the data were tested for 
normality where those with p>0.05 show normal distribution. For normally 
distributed sets, equal variance was tested between each active site. A 2-
sample t-test was used for those of equal variance, whilst a non-parametric 
Mann-Whitney test was used for results not of equal variance, to test for 
significance (p-values of <0.05 show statistical difference). 
Results 
Kinetic assays 
To assess the inhibitory activity of argyrin B against the immunoproteasome 
we performed kinetic assays using recombinant proteasome and 
immunoproteasome and β1c, β1i, β5c and β5i site-specific substrates(Miller, 
Ao, Kim, & Lee, 2013). The β2c and  β2i sites were excluded from testing 
since as revealed by the crystal structures their active sites are remarkably 
similar and thus a difference in the binding affinity of inhibitors towards β2c 
and  β2i is not expected(Huber et al., 2012). To determine the IC50 values 
(Figure 2) the substrate concentration was chosen at the Km value in order to 
avoid unrepresentative values from different inhibition modes(Cheng & 
Prusoff, 1973) (Michaelis-Menten plots shown in Figure S1 in Supporting 
information). The highest binding affinity that argyrin B achieved was for the 
β5i site with an IC50 of 3.54 µM, followed by β5c and β1i with IC50 of 8.30 µM 
and 8.76 µM, respectively. The affinity of argyrin B for the β1c site was much 
lower with IC50 of 146.5 µM, showing a 16-fold selectivity towards β1i over 
β1c (Table 1). Kinetic analysis further supported our data where the Ki for the 
β1c site was estimated to be larger than 100 µΜ (Table 1). An accurate value 
for the Ki for β1c could not be determined due to the high concentration of 
argyrin B at 3 x IC50 (439.5 µM) that was required to carry out the β1c Ki 
range tests. At this concentration the amount of DMSO that is required to 
dissolve argyrin B is high enough to have a significant impact on enzyme-
substrate reaction. Kinetic analysis revealed similar inhibition constants for β1i 
and β5i with estimated Ki 5.21 and 6.61 µΜ, respectively, followed by β5c with 
Ki 13.85 µΜ. Over 20-fold selectivity of β1i over the β1c site is observed. 
Ki values were determined based on a non-competitive model, which proved 
to be the best fit based on AICc analysis(Kakkar, Pak, & Mayersohn, 2000). 
The non-competitive model and estimated Ki values were also supported by 
alternative analysis methods including Cornish-Bowden and Dixon plots as 
well as a conventional Hanes-Woolf plot (Figure S2-S5).   
Despite inhibiting non-competitively, argyrin B can still bind at the active site 
as reported for other members of the argyrin family(Loizidou & Zeinalipour-
Yazdi, 2014; Stauch et al., 2010) as well as the β5c, β5i asparagine-
ethylenediamine-based inhibitors(Santos et al., n.d.). Non-competitive binding 
can potentially be beneficial in a cell environment were protein degradation is 
inhibited leading to progressive accumulation of substrate, as the 
concentration of substrate would not influence the degree of inhibition.  
Molecular docking 
 
Molecular docking was employed to shed light on the possible mechanisms of 
selective inhibition exhibited by argyrin B towards the immunoproteasome. 
Based on existing knowledge that argyrin analogues bind near the active site 
of the proteasome(Stauch et al., 2010), the grid box was centered at the β1i, 
β5i and β1c, β5c active sites for the molecular docking studies with argyring B. 
The active sites were simulated by using the three-dimensional structure for 
the human constitutive proteasome and a homology model of the human 
immunoproteasome that was generated using the crystal structure of the 
mouse immunoproteasome as the template (Figure S6, S7 and Table S1). 
Compared to the β1c active site, β1i is smaller in size and has a more 
hydrophobic character. This is exemplified by the key substitutions from 
constitutive to immunoproteasome in residues of the S1 specificity pocket, 
T22V, T33F, R47L, T52A (Figure 3). Apart from the conservative R47L 
subsitution, all others involve changing of a polar amino acid to a hydrophobic 
amino acid and as such, provide a hydrophobic character. Additionally, the 
β1i site is short of one amino acid, at position 115, which is consistent with the 
reported sequences for β1i(Huber et al., 2012).  
The binding of argyrin B at both β1i and β1c sites was found to be mainly 
driven by VdW, hydrogen bonding and desolvation interactions with argyrin B 
displaying a significant difference in binding preference towards β1i (-11.83 
kcal/mol) compared to β1c (-10.12 and -9.74 kcal/mol). One main binding 
conformation was identified at the β1i site showing great consistency of 
interactions between argyrin B and amino acids of the β1i active site. Αrgyrin 
B is positioned close to Thr1, which participates in two hydrogen bonding 
interactions with the thiazole nitrogen of argyrin B as well as an additional 
hydrogen bond with the adjacent carbonyl oxygen. The latter is further 
stabilized by a hydrogen bond with Ser129. Additional hydrogen bonding were 
identified between trp 1 of argyrin B and Ser46 as well as between an amide 
backbone of the argyrin macrocycle and Val 20. VdW interactions were 
identified between argyrin B and the amino acids Ala49, Arg19, His97, Met5, 
Ser48, Val20, Gly128, Gly47, Ala96, Leu115 and Tyr30. Additionally, Ser95 is 
likely to be involved in dipole-dipole interactions with trp 2 of argyrin B. 
In contrast, molecular modeling suggested a dual binding mode for argyrin B 
at the active site of β1c, where interactions with residues Arg35, Gly47, 
Met116, and Met95, appear in both conformations. The two binding 
conformations appear at a 2:3 ratio. At the more abundant binding 
conformation 1 (Fig. 3C,D) argyrin B is positioned close to Thr1 forming a 
similar hydrogen bond with the thiazole ring which is further stabilized through 
a second hydrogen bond with Gly47. Additional hydrogen bonding interactions 
were identified between the amino acids Thr22 and backbone carbonyl of 
argyrin B as well as Met116 and trp2. Trp1 is surrounded by residues Arg35, 
Gly97, Gly129, Ser130 and Ser46 forming VdW interactions. Additional VdW 
interactions were between the amino acids Thr20, Thr21, Gly23, Ala49, Met95, 
and Val20 and the cyclic backbone of argyrin B. 
In the less frequently occurring but more energetically favored (-10.12 
kcal/mol compared to -9.74 kcal/mol) conformation 2, argyrin B is positioned 
further away from Thr1 enabling aromatic interactions between Tyr30 and the 
tryptophan rings of argyrin B (Fig. 3E-F). Hydrogen bonding interactions are 
observed with amino acids Arg35, Gly97, and Gly128 and VdW interactions 
with amino acids Gly129, Pro115, Met116, Gly47, Met95, Met5, Tyr30, Leu33, 
Ser133, at β1c.  
Overall there are 5 hydrogen-bonding interactions in β1i compared to 4 
hydrogen-bonding interactions in β1c conformation 1, offering the extra 
stabilisation. It is likely that the more compact size of the β1i site compared to 
the β1c allows for a better fit for argyrin B and the facilitation of interactions 
with amino acids of the active site. On the other hand, the more spacious β1c 
site allows argyrin B to adopt several binding conformations and this is 
exemplified by the two main binding modes identified by molecular modelling. 
Similarly to the β1 sites, the binding of argyrin B at both β5i and β5c sites was 
found to be mainly driven by VdW, hydrogen bonding and desolvation 
interactions. One main binding conformation was identified at the β5i site 
showing great consistency of interactions between argyrin B and amino acids 
of the β5i active site (Figure 4A,B). Four main hydrogen-bonding interactions 
were identified with residues Thr1, Ser21 and Ser46. VdW interactions were 
identified with amino acids Val31, Ala49, Met45 and Lys33, which surround 
trp1 of argyrin B as well as amino acids Gly47, Gly129 and Tyr169.   
A dual binding mode was identified at the β5c site of the constitutive 
proteasome. In β5c, the frequency of appearance of the two main 
conformations follows a similar pattern to β1c, that is a 2:3 ratio for β5c 
conformation 1 (binding energy -10.52 kcal/mol) vs β5c conformation 2 
(binding energy – 10.72 kcal/mol) where both conformations show similar 
binding energies. In both binding conformations argyrin B binds in a similar 
area but the tryptophan rings are positioned on opposite sites (Figure 4C-F). 
In conformation 1 (Figure 4C), argyrin B forms three hydrogen-bonding 
interactions with Gly47, Gly129 and Ser130. The remaining interactions are 
VdW with amino acids Thr1, Ser96, Ser116, Asp115, Tyr113, Glu117, Ser23, 
Asn24, Tyr134, Ala32, Asp167 and Tyr169. In this conformation the 
tryptophan rings of argyrin B are interacting primarily with polar amino acids 
including, Ser96, Ser116, Asp115, Glu117 and Tyr113 in which the hydroxyl 
group is facing towards the tryptophan rings. 
In conformation 2 (Figure 4E), argyrin B forms two hydrogen-bonding 
interactions with Gly47 and Asn24. The remaining interactions are VdW with 
amino acids Val133, Phe137, Gln33, Ile30, Ala32, Tyr169, Ser130, Gly129, 
Val128, Thr1, Ala46, Gly98, Glu117, Tyr113. In this second conformation, trp1 
of argyrin B is surrounded by residues Tyr169, Ala32, Gln33, Ile30 and 
Phe137 forming primarily hydrophobic interactions. 
The energetics of binding are similar for β5i and β5c. In β5i, all bonding is 
based around the Trp moieties whilst no residues strongly interacted at the 
opposing end of the inhibitor. The tryptophan rings of argyrin B wrapped 
around Ser46, each forming hydrogen bonds. Argyrin B interacted with 
residues only from the β5i subunit in the immunoproteasome, whereas 
conformations within the constitutive proteasome also displayed interactions 
with nearby subunit chains i.e, Ser23 and Asn24 from the neighbouring β4 
and Ala32 from β3. 
Comparing the β5 sites of both the human constitutive and 
immunoproteasomes (Figure S8), they appear to be remarkably conserved 
amongst key residues that confer chymotrypsin-like activity Ala20, Met45, 
Ala49 and Cys52(Huber et al., 2012) however, the substitutions at the key 
residues, A46S and T128V (from β5c to β5i) surrounding Thr1, as well as the 
G48C (from β5c to β5i) substitution at the S3 pocket, give the β5i site a more 
polar character and also have a role in defining the shape of the active 
site(Huber et al., 2012). Keeping this in mind, the A27S substitution enables 
the formation of the hydrogen bond between argyrin B and S27 at the β5i site, 
which is not possible with A27 at β5c. Overall however, the predicted binding 
energies of argyrin B are not statistically different over the two β5 sites (Table 
2). 
Discussion 
Argyrins are known inhibitors of the constitutive proteasome that bind 
reversibly at the active site(Loizidou & Zeinalipour‐Yazdi, 2014; Loizidou & 
Zeinalipour-Yazdi, 2014). In this study we showed that argyrin B, inhibits the 
constitutive proteasome and immunoproteasome non-competitively and 
shows greater selectivity towards the β1i site of the immunoproteasome with 
IC50 and Ki values at low µΜ range. Within the immunoproteasome, argyrin B 
did not show subunit selectivity as both β5i and β1i are inhibited with similar 
potency. This is potentially advantageous as studies have shown that the 
cytotoxicity of proteasome inhibitors does not correlate with β5-inhibition and 
that the simultaneous inhibition with either β1 or β2 is needed to reduce 
protein degradation(Britton et al., 2009a; Alexei F. Kisselev, Callard, & 
Goldberg, 2006; Weyburne et al., 2017). This is further supported by the study 
of Britton et al. who showed that maximal cytotoxicity in cells is achieved 
when proteasome inhibitors target more than one sites(Britton	  et	  al.,	  2009b). 
A possible explanation for this is allosteric interactions between active sites in 
which inactivation of one site by an inhibitor would lead to the other two sites 
compensating for loss of activity (A. F. Kisselev, Akopian, Castillo, & Goldberg, 
1999). To this end, Weyburne et al.(Weyburne et al., 2017) showed that co-
inhibition of β2 enhances the inhibitory activity of FDA approved β5 
proteasome inhibitors to triple-negative breast cancer cells, by blocking 
recovery of proteasome activity. These studies support the hypothesis that 
subunit specific proteasome inhibitors may not lead to clinically useful drugs 
and that in contrast efforts should be focused on immunoproteasome over 
proteasome selectivity.  
The ability of argyrin B to inhibit all sites of the proteasome has also been 
documented by Bülow et al.(Bülow et al., 2010) who also reported an IC50 
value for argyrin B at 4.6 nM from MTT cytotoxicity assays in SW-480 colon 
cancer cells. This assay measures overall metabolic activity to reflect cell 
viability and therefore also reflects the overall effect of inhibition of all 
proteasome sites. In other words, argyrin B inhibits more than one sites of the 
proteasome leading to a synergistic effect of each active site inhibition and an 
overall lower IC50 value (4.6 nM). In this project, the possibility of synergistic 
inhibition could not be evaluated, as the inhibition of each active site was 
determined independently which also explains the higher IC50 values that are 
observed in this study (Table 1). A strong correlation has been observed 
between theoretical and experimental studies. Molecular modelling predicts 
that argyrin B will bind the strongest to β1i, followed by β5i, β5c and last to 
β1c, this trend is also confirmed from the inhibition kinetics experiments 
(Table 2). Argyrin B interacts with the β1i and β5i sites of the 
immunoproteasome with higher affinity than the corresponding sites of the 
constitutive proteasome. In the case of the immunoproteasome, binding is 
facilitated by additional hydrogen bonding compared to the constitutive 
proteasome and this was made possible due to either a better fit within the 
active site (the case for β1i) or an amino acid variation from constitutive to 
immunoproteasome, A27S for the case of β5i.  
Taken together, these results further highlight the feasibility of designing 
immunoproteasome selective inhibitors facilitated by molecular modeling. At 
the same time, the identification of a non-competitive reversible inhibitor of the 
immunoproteasome with selectivity towards β1i shows great promise for the 
development of therapeutics associated with reduced toxicity. 
 
Supporting information:  
Supporting information includes Michaelis-Menten plots to determine Km for 
each active site; Dixon plot; Cornish Bowden plot; Hanes-Wolf plot at β1i; 
BLAST alignments from murine β1i and β5i active sites to human sequence; 
amino acid substitutions performed to prepare the humanized 
immunoproteasome models; sequence alignment of human constitutive 
proteasome and humanised immunoproteasome sites. PDB coordinates of 
best-docked conformations and catalytic active sites are provided as separate 
documents. 
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Tables: 
Table 1. Summary of IC50 and Ki analysis at β1c, β1i, β5c and β5i. * denotes 
statistical significance from t-test. 
 β1c β1i β5c β5i 
IC50 (µΜ) 146.5* 8.76 8.30 3.54 
SE 1.10 1.08 1.07 1.08 
95% CI 122.3-175.5 7.6-10.1 7.8-9.4 3.0-4.1 
Ki (µΜ) >100 5.21 13.85 6.61 
SE - 0.34 0.96 0.49 
95% CI - 4.54-5.89 11.93-15.76 5.63-7.59 	  
Table 2. Comparison of estimated binding energies from molecular modeling 
and inhibition constants from kinetic assays 
 
 β1 β5 
 CP IP CP IP 
Lowest binding 
energy (kcal/mol) 
-9.74 (conf.1) 
-10.12 (conf.2) -11.83 
-10.52 (conf.1) 
-10.72 (conf.2) -10.97 
Average binding 
energy (kcal/mol) -9.81 -11.66 -10.58 -10.73 
SE 0.062 0.045 0.027 0.056 
Calculated Ki 
from assays (µΜ) >100 5.21 13.85 6.61 
 
 
 
Figure legends: 
Figure 1. Chemical structure of argyrin B.   
 
Figure 2. Argyrin B IC50 plots at β1c, β1i, β5c, β5i sites. Logarithmic argyrin B 
concentration against percentage control, initial rate velocity. Tested at [CP] 
and [IP] = 0.1 µg/well and [S] = Km (Km values: β1c = 95.4 µΜ, β1i = 69.9 µΜ, 
β5c = 72.4 µΜ, β5i = 89.8 µΜ). Non-linear regression analysis with variable 
hill slope and 1/y2 weighting generated IC50 values with respective SEM from 
3 independent repeats. A) β1i IC50 = 8.76 µM +/-1.08, β1c IC50 = 146.5 µM +/-
1.10.  B) β5c = 8.30 µM +/- 1.07, β5i = 3.54 µM +/- 1.08. DMSO solvent 
controls used where applicable. 
 
Figure 3. Best-docked conformations of argyrin B (shown as stick 
representation) at the β1i (A and B) and β1c (C-F) active sites. A) Best-
docked conformation of argyrin B at β1i active site, enzyme shown as 
magenta cartoon representation. Hydrogen bonding interactions between 
argyrin B and amino acids Thr1, Ser21, Ser46 and Ser129 are shown as 
green dotted lines. B) Best-docked conformation of argyrin B at β1i active site, 
enzyme is shown as surface representation where colours red, blue, yellow, 
magenta correspond to oxygen, nitrogen, sulfur and carbon elements; C) 
Best-docked conformation 1 of argyrin B at β1c active site, enzyme is shown 
as teal cartoon representation. Hydrogen bonding interactions between 
argyrin B and amino acids Thr1, Gly47, Thr22 and Met116 are shown as 
green dotted lines; D) Best-docked conformation 1 of argyrin B at β1c active 
site, enzyme is shown as surface representation where colours red, blue, 
yellow, teal correspond to oxygen, nitrogen, sulfur and carbon elements.  
E) Best-docked conformation 2 of argyrin B at β1c active site, enzyme is 
shown as teal cartoon representation. Hydrogen bonding interactions between 
argyrin B and amino acids Arg35, Gly97, and Gly128 are shown as green 
dotted lines; F) Best-docked conformation 2 of argyrin B at β1c active site, 
enzyme is shown as surface representation where colours red, blue, yellow, 
teal correspond to oxygen, nitrogen, sulfur and carbon elements.  
 
Figure 4. Best-docked conformations of argyrin B (shown as stick 
representation) at the β5i (A and B) and β5c (C-F) active sites. A) Best-
docked conformation of argyrin B at β5i active site, enzyme shown as light 
blue cartoon representation. Hydrogen bonding interactions between argyrin 
B and amino acids Thr1, Ser21 and Ser46 are shown as green dotted lines. 
B) Best-docked conformation of argyrin B at β5i active site, enzyme is shown 
as surface representation where colours red, blue, yellow, light blue 
correspond to oxygen, nitrogen, sulfur and carbon elements; C) Best-docked 
conformation 1 of argyrin B at β5c active site, enzyme is shown as light pink 
cartoon representation. Hydrogen bonding interactions between argyrin B and 
amino acids Gly47, Gly129 and Ser130 are shown as green dotted lines; D) 
Best-docked conformation 1 of argyrin B at β5c active site, enzyme is shown 
as surface representation where colours red, blue, yellow, light pink 
correspond to oxygen, nitrogen, sulfur and carbon elements.  
E) Best-docked conformation 2 of argyrin B at β5c active site, enzyme is 
shown as light pink cartoon representation. Hydrogen bonding interactions 
between argyrin B and amino acids Asn24 and Gly47 are shown as green 
dotted lines; F) Best-docked conformation 2 of argyrin B at β5c active site, 
enzyme is shown as surface representation where colours red, blue, yellow, 
light pink correspond to oxygen, nitrogen, sulfur and carbon elements.  
 
 
